# Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

> **NCT05802836** · — · RECRUITING · sponsor: **Christoph Königs** · enrollment: 100 (estimated)

## Conditions studied

- Severe Hemophilia A
- Severe Hemophilia A With Inhibitor
- Severe Hemophilia A Without Inhibitor

## Interventions

- **OTHER:** no interventions

## Key facts

- **NCT ID:** NCT05802836
- **Lead sponsor:** Christoph Königs
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05802836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05802836, "Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05802836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*